Preclinical immunogenicity and protective efficacy of an oral Helicobacter pylori inactivated whole cell vaccine and multiple mutant cholera toxin: A novel and non-toxic mucosal adjuvant. Issue 41 (1st October 2018)

• Record Type: Journal Article
• Authors: Holmgren, Jan; Nordqvist, Stefan; Blomquist, Margareta; Jeverstam, Frida; Lebens, Michael; Raghavan, Sukanya
• Is Part Of: Vaccine. Volume 36:Issue 41(2018)
• Page Start: 6223
• Page End: 6230
• Publication Date: 2018-10-01
• Subjects: CT cholera toxin -- FCS fetal calf serum -- mmCT multiple mutant cholera toxin -- IG intragastric -- SL sublingual; Helicobacter pylori -- Whole cell vaccines -- Adjuvants -- Cytokines; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2018.07.073
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: Mucosal vaccines against Helicobacter pylori consisting of either whole cell bacteria or recombinant antigens can induce immune protection against challenge in mice only when co-administrated with a strong mucosal adjuvant such as cholera toxin (CT) or Escherichia coli heat labile enterotoxin (LT). The strong enterotoxicity of these adjuvants however preclude their use in human vaccines. The recently developed multiple mutant CT (mmCT) is a strong, yet practically non-toxic novel mucosal adjuvant which here was admixed with a formalin-inactivated H. pylori whole cell vaccine (WCV) as a potential vaccine candidate against H. pylori infection. We report that intragastric immunizations with H. pylori WCV together with mmCT, similar to immunization with WCV together with CT, resulted in 50–125-fold reduction in colonization of H. pylori in the stomach of mice associated with rises in both serum IgG and intestinal-mucosal IgA anti- H. pylori antibody responses and strong T cell and IFNγ and IL-17A cytokine responses. Data presented in this study also supports that the proposed vaccine can be grown in a bioreactor and would be effective against infection caused by a multitude of pathogenic H. pylori strains isolated from patients from various continents. The results warrant immunization studies in humans to evaluate the safety, immunogenicity and efficacy of the proposed H. pylori WCV and mmCT.